MCID: DRM010
MIFTS: 59

Dermatomyositis

Categories: Rare diseases, Neuronal diseases, Nephrological diseases, Bone diseases, Skin diseases, Muscle diseases

Aliases & Classifications for Dermatomyositis

MalaCards integrated aliases for Dermatomyositis:

Name: Dermatomyositis 12 50 51 56 52 42 14 69
Amyopathic Dermatomyositis 12 50 69
Adult Dermatomyositis 50 56
Polymyositis with Skin Involvement 12
Dermatomyositis Sine Myositis 50
Adult Type Dermatomyositis 69
Dermatopolymyositis 12
Adm 50
Dm 56

Characteristics:

Orphanet epidemiological data:

56
dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Argentina),1-5/10000 (Argentina),1-9/1000000 (United States),1-9/1000000 (Spain); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Dermatomyositis

NINDS : 51 Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Dermatomyositis’ cardinal symptom is a skin rash that precedes, accompanies, or follows  progressive muscle weakness.  The rash looks patchy, with purple or red discolorations, and characteristically develops on the eyelids and on muscles used to extend or straighten joints, including knuckles, elbows, knees, and toes.  Red rashes may also occur on the face, neck, shoulders, upper chest, back, and other locations, and there may be swelling in the affected areas.  The rash sometimes occurs without obvious muscle involvement.  Adults with dermatomyositis may experience weight loss, a low-grade fever, inflamed lungs, and be sensitive to light such that the rash or muscle disease gets worse.  Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis).  Calcinosis most often occurs 1-3 years after the disease begins.  These deposits are seen more often in children with dermatomyositis than in adults.  In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Dermatomyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. 

MalaCards based summary : Dermatomyositis, also known as amyopathic dermatomyositis, is related to chromophobe renal cell carcinoma and childhood type dermatomyositis, and has symptoms including recurrent respiratory infections, fatigue and pericarditis. An important gene associated with Dermatomyositis is IFIH1 (Interferon Induced With Helicase C Domain 1), and among its related pathways/superpathways are AGE-RAGE signaling pathway in diabetic complications and Rheumatoid arthritis. The drugs Abatacept and Pirfenidone have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and breast, and related phenotype is mortality/aging.

Disease Ontology : 12 A myositis that results_in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction.

NIH Rare Diseases : 50 amyopathic dermatomyositis is a form of dermatomyositis characterized by the presence of typical skin findings without muscle weakness. some of the skin changes that suggest dermatomyositis include a pink rash on the face, neck, forearms and upper chest; gottron's papules and heliotrope eyelids. pruritis and photosensitivity are common, as is scalp inflammation and thinning of the hair. while patients with amyopathic dermatomyositis should not have clinically evident muscle weakness, minor muscle abnormalities may be included. fatigue is reported in at least 50% of patients. some cases have been associated with internal malignancy and/or interstitial lung disease. treatment may include sun avoidance, ample use of sunscreen, topical corticosteroids, antimalarial agents, methotrexate, mycophenolate mofetil, or intravenous (iv) immunoglobulin. last updated: 1/10/2013

Wikipedia : 72 Dermatomyositis (DM) is a long term inflammatory disorder which affects muscles. Symptoms generally a... more...

Related Diseases for Dermatomyositis

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
id Related Disease Score Top Affiliating Genes
1 chromophobe renal cell carcinoma 29.5 IFIH1 MORC3
2 childhood type dermatomyositis 12.3
3 adult dermatomyositis 12.0
4 neonatal dermatomyositis 11.9
5 c9 deficiency 11.6
6 polymyositis 11.4
7 myositis 11.4
8 myotonic dystrophy 1 11.3
9 maturity-onset diabetes of the young 11.2
10 diabetes insipidus 11.2
11 idiopathic inflammatory myopathy 11.1
12 antisynthetase syndrome 11.1
13 juvenile polymyositis 11.1
14 cryptogenic organizing pneumonia 11.1
15 epidermolysis bullosa simplex, dowling-meara type 11.1
16 diaphyseal medullary stenosis with malignant fibrous histiocytoma 10.8
17 myopathy, distal, tateyama type 10.5 CHKB PIK3C2A
18 velocardiofacial syndrome 10.5 CHKB PIK3C2A
19 lymphomatous thyroiditis 10.4 ICAM1 VCAM1
20 lung disease 10.4
21 interstitial lung disease 10.4
22 heart lymphoma 10.3 ICAM1 VCAM1
23 calcinosis 10.3
24 marginal corneal ulcer 10.3 ICAM1 VCAM1
25 dentin dysplasia 10.2 ICAM1 PIK3C2A VCAM1
26 epstein-barr virus hepatitis 10.2 IL1A PIK3C2A
27 autoimmune lymphoproliferative syndrome due to ctla4 haploinsuffiency 10.1 ICAM1 IL17A
28 lupus erythematosus 10.1
29 pneumonia 10.1
30 liver disease 10.0 ICAM1 IL1A VCAM1
31 orbital melanoma 10.0 ICAM1 IL1A VCAM1
32 arthritis 10.0
33 myopathy 10.0
34 inclusion body myositis 10.0
35 systemic lupus erythematosus 10.0
36 melanoma 10.0
37 cerebellar disease 9.9 ICAM1 IL17A IL1A
38 panniculitis 9.9
39 aortic arch anomaly - peculiar facies - intellectual disability 9.9 HARS KARS TARS
40 lymphoma 9.9
41 esophageal candidiasis 9.9 ICAM1 IL17A IL1A
42 breast cancer 9.9
43 rheumatoid arthritis 9.9
44 chickenpox 9.8 ICAM1 S100A9 VCAM1
45 juvenile overlap myositis 9.8
46 adenocarcinoma 9.8
47 cutaneous lupus erythematosus 9.8
48 neonatal jaundice 9.8 ICAM1 IL17A MX1
49 skin disease 9.8
50 nasopharyngitis 9.8

Comorbidity relations with Dermatomyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Polymyositis

Graphical network of the top 20 diseases related to Dermatomyositis:



Diseases related to Dermatomyositis

Symptoms & Phenotypes for Dermatomyositis

Human phenotypes related to Dermatomyositis:

56 32 (show top 50) (show all 52)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent respiratory infections 56 32 frequent (33%) Frequent (79-30%) HP:0002205
2 fatigue 56 32 frequent (33%) Frequent (79-30%) HP:0012378
3 pericarditis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001701
4 arthritis 56 32 frequent (33%) Frequent (79-30%) HP:0001369
5 myalgia 56 32 hallmark (90%) Very frequent (99-80%) HP:0003326
6 fever 56 32 occasional (7.5%) Occasional (29-5%) HP:0001945
7 dry skin 56 32 frequent (33%) Frequent (79-30%) HP:0000958
8 respiratory insufficiency 56 32 frequent (33%) Frequent (79-30%) HP:0002093
9 cellulitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0100658
10 proximal muscle weakness 56 32 hallmark (90%) Very frequent (99-80%) HP:0003701
11 muscular hypotonia 56 32 frequent (33%) Frequent (79-30%) HP:0001252
12 feeding difficulties in infancy 56 32 occasional (7.5%) Occasional (29-5%) HP:0008872
13 lymphoma 56 32 occasional (7.5%) Occasional (29-5%) HP:0002665
14 weight loss 56 32 frequent (33%) Frequent (79-30%) HP:0001824
15 dysphonia 56 32 occasional (7.5%) Occasional (29-5%) HP:0001618
16 pruritus 56 32 frequent (33%) Frequent (79-30%) HP:0000989
17 vasculitis 56 32 occasional (7.5%) Occasional (29-5%) HP:0002633
18 myocardial infarction 56 32 occasional (7.5%) Occasional (29-5%) HP:0001658
19 breast carcinoma 56 32 occasional (7.5%) Occasional (29-5%) HP:0003002
20 gangrene 56 32 occasional (7.5%) Occasional (29-5%) HP:0100758
21 acrocyanosis 56 32 frequent (33%) Frequent (79-30%) HP:0001063
22 periorbital edema 56 32 hallmark (90%) Very frequent (99-80%) HP:0100539
23 lung adenocarcinoma 56 32 occasional (7.5%) Occasional (29-5%) HP:0030078
24 arthralgia 56 32 frequent (33%) Frequent (79-30%) HP:0002829
25 erythema 56 32 hallmark (90%) Very frequent (99-80%) HP:0010783
26 pulmonary fibrosis 56 32 frequent (33%) Frequent (79-30%) HP:0002206
27 myocarditis 56 32 occasional (7.5%) Occasional (29-5%) HP:0012819
28 diffuse reticular or finely nodular infiltrations 56 32 frequent (33%) Frequent (79-30%) HP:0002207
29 sinus tachycardia 56 32 occasional (7.5%) Occasional (29-5%) HP:0011703
30 chondrocalcinosis 56 32 frequent (33%) Frequent (79-30%) HP:0000934
31 cutaneous photosensitivity 56 32 occasional (7.5%) Occasional (29-5%) HP:0000992
32 abnormality of the nail 56 32 frequent (33%) Frequent (79-30%) HP:0001597
33 emg abnormality 56 32 hallmark (90%) Very frequent (99-80%) HP:0003457
34 autoimmunity 56 32 hallmark (90%) Very frequent (99-80%) HP:0002960
35 skin ulcer 56 32 frequent (33%) Frequent (79-30%) HP:0200042
36 abnormal hair quantity 56 32 frequent (33%) Frequent (79-30%) HP:0011362
37 abnormality of the eyelid 56 32 hallmark (90%) Very frequent (99-80%) HP:0000492
38 aplasia/hypoplasia of the skin 56 32 occasional (7.5%) Occasional (29-5%) HP:0008065
39 abnormality of eosinophils 56 32 occasional (7.5%) Occasional (29-5%) HP:0001879
40 papule 56 32 frequent (33%) Frequent (79-30%) HP:0200034
41 inflammatory myopathy 56 32 hallmark (90%) Very frequent (99-80%) HP:0009071
42 gastrointestinal stroma tumor 56 32 occasional (7.5%) Occasional (29-5%) HP:0100723
43 pulmonary hypertension 56 Occasional (29-5%)
44 arrhythmia 56 Occasional (29-5%)
45 edema 56 Very frequent (99-80%)
46 pulmonary arterial hypertension 32 occasional (7.5%) HP:0002092
47 neoplasm 56 Occasional (29-5%)
48 teleangiectasia of the skin 56 Occasional (29-5%)
49 abnormality of the voice 56 Occasional (29-5%)
50 interstitial pulmonary disease 56 Frequent (79-30%)

UMLS symptoms related to Dermatomyositis:


exanthema, pruritus

MGI Mouse Phenotypes related to Dermatomyositis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.4 KARS MORC3 PIK3C2A S100A9 UTRN VCAM1

Drugs & Therapeutics for Dermatomyositis

Drugs for Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
2
Pirfenidone Investigational Phase 4 53179-13-8 40632
3 Vaccines Phase 4
4 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
5 Hormones Phase 4,Phase 3,Phase 2,Phase 1
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Adrenocorticotropic Hormone Phase 4,Phase 2
12 beta-endorphin Phase 4,Phase 2
13 Melanocyte-Stimulating Hormones Phase 4,Phase 2
14 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
17
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
18
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
21
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
22
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
23
Benzocaine Approved Phase 2, Phase 3 1994-09-7, 94-09-7 2337
24
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492
25
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
26
Infliximab Approved Phase 2, Phase 3 170277-31-3
27
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
28
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
29
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
30
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
31
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
33
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
34 tannic acid Approved, Nutraceutical Phase 2, Phase 3
35 Antiemetics Phase 3,Phase 2
36 Antifungal Agents Phase 3,Phase 2
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1
38 Antimetabolites Phase 3,Phase 2
39 Antimetabolites, Antineoplastic Phase 3,Phase 2
40 Antineoplastic Agents, Hormonal Phase 3,Phase 2
41 Autonomic Agents Phase 3,Phase 2
42 Calcineurin Inhibitors Phase 3,Phase 2
43 Cyclosporins Phase 3,Phase 2
44 Dermatologic Agents Phase 3,Phase 2
45 Folic Acid Antagonists Phase 3,Phase 2
46 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
47 glucocorticoids Phase 3,Phase 2,Phase 1
48 Methylprednisolone acetate Phase 3,Phase 2
49 Methylprednisolone Hemisuccinate Phase 3,Phase 2
50 Neuroprotective Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 80)

id Name Status NCT ID Phase Drugs
1 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4 Human papilloma virus vaccine (cervarix)
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
5 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
6 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Not yet recruiting NCT02821689 Phase 4 Pirfenidone
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
8 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Unknown status NCT00504348 Phase 2, Phase 3 Tacrolimus
9 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
10 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
11 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
12 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
13 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
14 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
15 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
16 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
17 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
18 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
19 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
20 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
21 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
22 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
23 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
24 Safety and Efficacy of BAF312 in Dermatomyositis Completed NCT02029274 Phase 2 BAF312 0.5 mg;BAF312 2 mg;BAF312 10 mg;Placebo to BAF312
25 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
26 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
27 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
28 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
29 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
30 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
31 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
32 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
33 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
34 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
35 Trial of IMO-8400 in Adult Patients With Dermatomyositis Active, not recruiting NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
36 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo;JBT-101 Open-label
37 A Study In Adults With Moderate To Severe Dermatomyositis Not yet recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
38 Basiliximab Treating Interstitial Pneumonia of CADM Not yet recruiting NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
39 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
40 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
41 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Withdrawn NCT01918904 Phase 2 Sodium thiosulfate;Placebo
42 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
43 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1 Etanercept;Placebo
44 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1
45 Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders Completed NCT00010335 Phase 1
46 Mycophenolate Mofetil in Systemic Sclerosis Completed NCT00433186 Phase 1 Mycophenolate Mofetil
47 Study of Tofacitinib in Refractory Dermatomyositis Recruiting NCT03002649 Phase 1 Tofacitinib
48 A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases Active, not recruiting NCT02780674 Phase 1
49 Creatine Supplementation in Pediatric Rheumatology Unknown status NCT01217320
50 The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis Unknown status NCT02267005

Search NIH Clinical Center for Dermatomyositis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: dermatomyositis

Genetic Tests for Dermatomyositis

Anatomical Context for Dermatomyositis

MalaCards organs/tissues related to Dermatomyositis:

39
Skin, Lung, Breast, Bone, T Cells, Heart, Testes

Publications for Dermatomyositis

Articles related to Dermatomyositis:

(show top 50) (show all 1315)
id Title Authors Year
1
Liposteroid therapy for juvenile and adult dermatomyositis: efficacy and side effects. ( 28361075 )
2017
2
State of the art on nailfold capillaroscopy in dermatomyositis and polymyositis. ( 28668440 )
2017
3
Juvenile dermatomyositis positive for anti-DNA mismatch repair enzyme antibodies. ( 28073708 )
2017
4
Clinical and Dermoscopic Features of the Scalp in 31 Patients with Dermatomyositis. ( 28879187 )
2017
5
Successful resection of liver metastasis detected by exacerbation of skin symptom in a patient with dermatomyositis accompanied by rectal cancer: a case report and literature review. ( 28054279 )
2017
6
Dermatomyositis revealing both a metastatic linitis plastica and hepatitis C virus infection. ( 28731019 )
2017
7
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. ( 28012490 )
2017
8
Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer. ( 28871260 )
2017
9
MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis. ( 28480196 )
2017
10
Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. ( 28490218 )
2017
11
Mammography Findings of Breast Calcinosis in a Patient With Dermatomyositis. ( 28816763 )
2017
12
Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis. ( 28836555 )
2017
13
Anti-dense Fine Speckled 70 Autoantibodies in Japanese Children with Dermatomyositis, Localized Scleroderma, and Idiopathic Arthritis with Iridocyclitis. ( 28461535 )
2017
14
Retinal Manifestations of Juvenile Dermatomyositis: Case Report of Bilateral Diffuse Chorioretinopathy with Paracentral Acute Middle Maculopathy and Review of the Literature. ( 28448730 )
2017
15
Environmental factors associated with disease flare in juvenile and adult dermatomyositis. ( 28444299 )
2017
16
How can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment options. ( 28952230 )
2017
17
Juvenile Dermatomyositis: Key Roles of Muscle Magnetic Resonance Imaging and Early Aggressive Treatment. ( 28911766 )
2017
18
Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. ( 27995057 )
2017
19
Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. ( 28077146 )
2017
20
GLIS3 and TYK2 Single Nucleotide Polymorphisms Are Not Associated with Dermatomyositis/Polymyositis in Chinese Han Population. ( 28846454 )
2017
21
Juvenile dermatomyositis/polymyositis and lymphoma. ( 28477693 )
2017
22
A Case of Dermatomyositis with Severe Myalgia and Muscle Weakness Testing Positive for Anti-melanoma Differentiation-associated Gene 5 Antibody. ( 28824190 )
2017
23
Human herpes virus-6 encephalitis causing severe anterograde amnesia associated with rituximab, azathioprine and prednisolone combination therapy for dermatomyositis. ( 28224486 )
2017
24
Paraneoplastic Dermatomyositis. ( 28457044 )
2017
25
Paraneoplastic Dermatomyositis Syndrome Presenting as Dysphagia. ( 28912913 )
2017
26
Recurrence of juvenile dermatomyositis 8A years after remission. ( 28050594 )
2017
27
Focal hyperkeratosis overlying the palmar faces of interphalangeal and metacarpophalangeal joints revealing a juvenile dermatomyositis. ( 28895209 )
2017
28
Positive Association between ANKRD55 Polymorphism 7731626 and Dermatomyositis/Polymyositis with Interstitial Lung Disease in Chinese Han Population. ( 28470010 )
2017
29
Altered chemokine receptor expression in the peripheral blood lymphocytes in polymyositis and dermatomyositis. ( 28869080 )
2017
30
Triple cancers concurrently detected in a case of antitranscriptional intermediary factor-1I^ antibody-positive dermatomyositis. ( 28884788 )
2017
31
Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. ( 28451794 )
2017
32
2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. ( 28385805 )
2017
33
Amyopathic Dermatomyositis Associated with Histopathological Findings of Organizing Pneumonia and Pulmonary Vasculitis. ( 28443580 )
2017
34
Race and income affects outcomes in juvenile dermatomyositis. ( 28434566 )
2017
35
Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis. ( 28842784 )
2017
36
Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. ( 28460448 )
2017
37
Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. ( 28488124 )
2017
38
Quinacrine Suppresses Tumor Necrosis Factor-I+ and IFN-I+ in Dermatomyositis andA Cutaneous Lupus Erythematosus. ( 28941496 )
2017
39
Using multi-omics methods to understand dermatomyositis/polymyositis. ( 28778709 )
2017
40
Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA). ( 28934971 )
2017
41
Unsuspected Active Ulcerative Colitis in a Patient With Dermatomyositis: A Rare Association Detected on (18)F-FDG PET/CT During the Search for an Occult Malignancy. ( 28533643 )
2017
42
Endothelial progenitor cell number is not decreased in 34 children with Juvenile Dermatomyositis: a pilot study. ( 28514969 )
2017
43
Anti-SS-A/Ro antibody positivity as a risk factor for relapse in patients with polymyositis/dermatomyositis. ( 28463039 )
2017
44
Juvenile dermatomyositis: a tertiary center experience. ( 28058540 )
2017
45
A case of lipoatrophic diabetes induced by juvenile dermatomyositis. ( 28895299 )
2017
46
The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. ( 28711090 )
2017
47
Muscle ultrasound: a potential tool for detecting of fasciitis among dermatomyositis and polymyositis: Comment on article by Yoshida et al. ( 28853226 )
2017
48
Image Gallery: Palmoplantar hyperkeratosis in dermatomyositis with anti-PM/Scl antibodies. ( 28504398 )
2017
49
Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease. ( 28711881 )
2017
50
Myogenic progenitor cells exhibit IFN type I-driven pro-angiogenic properties and molecular signature during juvenile dermatomyositis. ( 28941175 )
2017

Variations for Dermatomyositis

Expression for Dermatomyositis

Search GEO for disease gene expression data for Dermatomyositis.

Pathways for Dermatomyositis

GO Terms for Dermatomyositis

Cellular components related to Dermatomyositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.65 AARS C9 GARS IARS ICAM1 PIK3C2A
2 cytosol GO:0005829 9.44 AARS C9 CHKB GARS HARS IARS
3 NuRD complex GO:0016581 9.32 CHD3 CHD4
4 aminoacyl-tRNA synthetase multienzyme complex GO:0017101 9.16 IARS KARS
5 cytoplasm GO:0005737 10.1 AARS CHD3 CHD4 GARS HARS IARS

Biological processes related to Dermatomyositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.72 ICAM1 IFIH1 KARS MORC3 VCAM1
2 regulation of translational fidelity GO:0006450 9.46 AARS IARS
3 response to copper ion GO:0046688 9.43 ICAM1 IL1A
4 translation GO:0006412 9.43 AARS GARS HARS IARS KARS TARS
5 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.4 IL17A KARS
6 tRNA aminoacylation GO:0043039 9.37 AARS TARS
7 membrane to membrane docking GO:0022614 9.26 ICAM1 VCAM1
8 diadenosine tetraphosphate biosynthetic process GO:0015966 9.16 GARS KARS
9 tRNA aminoacylation for protein translation GO:0006418 9.1 AARS GARS HARS IARS KARS TARS

Molecular functions related to Dermatomyositis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.9 AARS CHD3 CHD4 CHKB GARS HARS
2 zinc ion binding GO:0008270 9.85 CHD3 CHD4 IFIH1 MORC3 S100A9 UTRN
3 integrin binding GO:0005178 9.61 ICAM1 UTRN VCAM1
4 amino acid binding GO:0016597 9.46 AARS KARS
5 tRNA binding GO:0000049 9.43 AARS IARS KARS
6 ligase activity GO:0016874 9.43 AARS GARS HARS IARS KARS TARS
7 aminoacyl-tRNA editing activity GO:0002161 9.4 AARS IARS
8 ligase activity, forming aminoacyl-tRNA and related compounds GO:0016876 9.32 AARS TARS
9 aminoacyl-tRNA ligase activity GO:0004812 9.1 AARS GARS HARS IARS KARS TARS

Sources for Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....